Citations

Clear

3030 citation(s) found for "Susan, M".

Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
Kleinstern, Geffen , Boddicker, Nicholas , O’Brien, Daniel R. , Allmer, Cristine, Rabe, Kari G. , Waller, Rosalie G. , Yan, Huihuang , Ma, Tao , Call, Timothy G. , Bruins, Laura A., Brown, Sochilt , Campos, Cecília Bonolo de , Hanson, Curtis A. , Leis, José F., Ding, Wei , Vachon, Celine M. , Oakes, Christopher C. , Parker, Alexander S. , Brander, Danielle M. , Weinberg, J. Brice , Furman, Richard R. , Shanafelt, Tait D. , Griffin, R. L. , Boddicker, Nicholas J , Waller, Rosalie G , Bruins, Laura, Bonolo de Campos, Cecilia, Vachon, Celine M. , Kay, Neil E , Cerhan, James R , Parikh, Sameer A , Braggio, Esteban , Slager, Susan L , Chaffee, Kari G. , Ding, Wei , Shanafelt, Tait D , Griffin, Rosalie , Norman, Aaron D. , Kay, Neil E. , Cerhan, James R. , Parikh, Sameer A. , Braggio, Esteban , Slager, Susan L.

Mayo Clinic

Blood Advances | February 15, 2024 | Volume: 8 | Issue: 9 | Pages: 2118-2129

10.1182/bloodadvances.2023012242 | PMID 38359367 Get It

Abstract High-count monoclonal B-cell lymphocytosis (HCMBL) is a precursor condition to chronic lymphocytic leukemia (CLL). We have shown that among individuals with HCMBL, the CLL-International Prognostic Index (CLL-IPI) is prognostic for time-to-first therapy (TTFT). Little is known about the prognostic impact of somatically mutated genes among individuals with HCMBL. We sequenced DNA from 371 individuals with HCMBL using a targeted sequencing panel of 59 recurrently mutated genes in CLL to identify high-impact mutations. We compared the sequencing results with that of our treatment-naïve CLL cohort (N = 855) and used Cox regression to estimate hazard ratios and 95% confidence intervals (CIs) for associations with TTFT. The frequencies of any mutated genes were lower in HCMBL (52%) than CLL (70%). At 10 years, 37% of individuals with HCMBL with any mutated gene had progressed requiring treatment compared with 10% among individuals with HCMBL with no mutations; this led to 5.4-fold shorter TTFT (95% CI, 2.6-11.0) among HCMBL with any mutated gene vs none, independent of CLL-IPI. When considering individuals with low risk of progression according to CLL-IPI, those with HCMBL with any mutations had 4.3-fold shorter TTFT (95% CI, 1.6-11.8) vs those with none. Finally, when considering both CLL-IPI and any mutated gene status, we observed individuals with HCMBL who were high risk for both prognostic factors had worse prognosis than patients with low-risk CLL (ie, 5-year progression rate of 32% vs 21%, respectively). Among HCMBL, the frequency of somatically mutated genes at diagnosis is lower than that of CLL. Accounting for both the number of mutated genes and CLL-IPI can identify individuals with HCMBL with more aggressive clinical course.
Seeing with greater clarity: Stakeholder ratings of blind spots in U.S. medical education
Tackett, Sean , Steinert, Yvonne , Mirabal, Susan , Reed, Darcy A. , Wright, Scott M. , Mirabal, Susan , Wright, Scott M

Mayo Clinic

Medical Teacher | February 1, 2024 | Volume: 46 | Issue: 4 | Pages: 580-583

10.1080/0142159x.2024.2308064 | PMID 38301361 Get It

Endoscopic Endonasal Transcavernous Hemipituitary Transposition for Resection of Invasive Prolactinoma: 2-Dimensional Operative Video
Caicedo, Diana C. Alvarez , Donaldson, Angela M. , Samson, Susan L. , Chaichana, Kaisorn L. , Almeida, João Paulo , Alvarez Caicedo, Diana C, Almeida, Joao Paulo

Mayo Clinic

Operative Neurosurgery | February 1, 2024 | Volume: 27 | Issue: 1 | Pages: 129-130

10.1227/ons.0000000000001075 | PMID 38299803 Get It

Abstract PR09: Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene
Abozaid, Mohamed , Munankarmy, Amik , Rao, Tara, Couch, Ronan E. , Persons, Benjamin R., Pesaran, Tina , Huang, Huaizhi , Hu, Chunling , Na, Jie , Abozaid, Mohamed, Lumby, Carolyn A. , Lyra, Paulo C. , Polley, Eric C. , Karam, Rachid , Yadav, Siddhartha , Monteiro, Álvaro N.A. , Boddicker, Nicholas , Domchek, Susan M. , Richardson, Marcy E , Couch, Fergus J.

Mayo Clinic

Cancer Research | February 1, 2024 | Volume: 84 | Issue: 3_Supplement_1 | Pages: PR09-PR09

10.1158/1538-7445.advbc23-pr09 Get It

Abstract Many germline BRCA2 missense variants of uncertain significance (VUS) remain to be clinically classified as pathogenic or benign. Here we identify 70 missense VUS in the DNA binding domain (DBD) of BRCA2 that partially reduced homologous recombination DNA repair activity of the protein in a homology directed DNA repair cell-based assay. CRISPR/cas9-based knockin of these variants reduced cell survival of haploid cells and conferred increased sensitivity to the PARP inhibitor Olaparib. Sequence alignment analysis found that the variants were highly conserved across species from pufferfish to human. Structural analysis showed that these variants are located predominantly in unstructured regions of the DBD. Case-control association studies showed that the hypomorphic variants conferred moderate risks of breast (OR:2.85; 95%CI:1.43-5.88) and ovarian cancer (OR:3.37; 95%CI:1.30-8.54) that were significantly different from risks associated with known pathogenic and benign variants. Cumulative lifetime risks of breast and ovarian cancer among carriers were estimated at 25% and 4.7%, respectively. Age at diagnosis of breast cancer among hypomorphs carriers was 55 years of age as opposed to 48 years of age for carriers of pathogenic variants. In addition, the combination of functional and other genetic data in an ACMG/AMP-like variant classification model reclassified 39 variants as likely pathogenic. This novel group of low penetrance missense variants further calibrate BRCA2 variant classification methods and have significant implications for the management of variant carriers. Citation Format: Huaizhi (Gilbert) Huang, Chunling Hu, Jie Na, Mohamed Abozaid, Amik Munankarmy, Tara Rao, Carolyn A. Dunn Lumby, Paulo Cilas Morais Lyra, Ronan E. Couch, Benjamin R. Persons, Eric C. Polley, Rachid Karam, Tina Pesaran, Siddhartha Yadav, Alvaro N.A. Monteiro, Nicholas J. Boddicker, Susan M. Domchek, Marcy E. Richardson, Fergus J. Couch. Functional and clinical characterization of hypomorphic missense variants in the BRCA2 cancer predisposition gene [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr PR09.
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis
Chey, William D. , Harris, Lucinda A. , Frazier, Rosita , Lacy, Brian E. , Edelstein, Susan , Yang, Yang , Zhao, Suling , Rosenbaum, David P. , Edelstein, Susan , Yang, Yang , Frazier, Rosita D , Lembo, Anthony , Brenner, Darren M. , Chang, Lin

Mayo Clinic

American Journal of Gastroenterology | January 31, 2024 | Volume: 119 | Issue: 5 | Pages: 937-945

10.14309/ajg.0000000000002685 | PMID 38294158 Get It

INTRODUCTION: This post hoc analysis evaluated the efficacy of tenapanor on abdominal symptoms in patients with irritable bowel syndrome with constipation. Abdominal symptoms assessed included pain, discomfort, bloating, cramping, and fullness. METHODS: The abdominal symptom data were pooled from 3 randomized controlled trials (NCT01923428, T3MPO-1 [NCT02621892], and T3MPO-2 [NCT02686138]). Weekly scores were calculated for each abdominal symptom, and the Abdominal Score (AS) was derived as the average of weekly scores for abdominal pain, discomfort, and bloating. The overall change from baseline during the 12 weeks was assessed for each symptom weekly score and the AS. The AS 6/12-week and 9/12-week response rates (AS improvement of ≥2 points for ≥6/12- or ≥9/12-week) were also evaluated. The association of weekly AS response status (reduction of ≥30%) with weekly complete spontaneous bowel movement (CSBM) status (=0 and >0) was assessed. RESULTS: Among 1,372 patients (684 tenapanor [50 mg twice a day] and 688 placebo), the least squares mean change from baseline in AS was −2.66 for tenapanor vs −2.09 for placebo ( P < 0.0001). The 6/12-week AS response rate was 44.4% for tenapanor vs 32.4% for placebo ( P < 0.0001), and for 9/12-week AS, 30.6% for tenapanor vs 20.5% for placebo ( P < 0.0001). A significant association between weekly CSBM status and weekly AS response status was observed each week ( P < 0.0001), with a greater proportion achieving an AS reduction in patients with >0 CSBMs in a week. DISCUSSION: Tenapanor significantly reduced abdominal symptoms in patients with irritable bowel syndrome with constipation, particularly pain, discomfort, and bloating measured by AS, compared with placebo.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Yacoub, Abdulraheem , Borate, Uma , Rampal, Raajit K. , Ali, Haris , Gerds, Aaron T. , Kremyanskaya, Marina , Winton, Elliott F., Goel, Swati , Schiller, Gary J. , McCloskey, James, Palmer, Jeanne , Holmes, Houston, Hager, Steven, Assad, Albert , Erickson‐Viitanen, Susan, Zhou, Feng , Gerds, Aaron T , Goel, Swati , Oh, Stephen T , Palmer, Jeanne M , Daver, Naval , Wang, Eunice S. , Hobbs, Gabriela , O'Connell, Casey Lee , Oh, Stephen T. , Daver, Naval

Mayo Clinic

Blood Advances | January 30, 2024 | Volume: 8 | Issue: 6 | Pages: 1515-1528

10.1182/bloodadvances.2023011620 | PMID 38290135 Get It

Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
An, Zesheng , Gicobi, Joanina K. , Xu, Tianxiao , Harrington, Susan M. , Hirdler, Jacob, Lohse, Christine M. , Pessoa, Rodrigo Rodrigues , Sharma, Vidit , Thompson, Houston R., Leibovich, Bradley C. , Hsu, Michelle A. , Zhang, Henan , Pavelko, Kevin D. , Hirdler, Jacob B. , Nabavizadeh, Reza , Thompson, Houston, Dong, Haidong , Lucien, Fabrice

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 458-458

10.1200/jco.2024.42.4_suppl.458 Get It

458 Background: Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 axis has revolutionized the therapeutic landscape of patients with advanced and locally advanced renal cell carcinoma (RCC). However, complete response rates remain low and there is a need for novel therapeutic options for ICI-resistant and refractory RCC. Our group has generated a novel humanized anti-PD-L1 antibody, called H1A, that induces PD-L1 degradation preventing not only its interaction with PD-1 but also inhibiting pro-tumorigenic intracellular signaling. In this study, we compared the antitumor activity of H1A with FDA-approved ICI using patient-derived immune cells and humanized mouse tumor models. Methods: In vivo antitumor activity of H1A and atezolizumab (ATZ) was compared in three humanized PD-1/PD-L1 mouse tumor models with different immunogenicity (E0771:high, MC38:moderate, B16-F10:poor). Peripheral blood mononuclear cells (PBMC) were isolated from 14 RCC patients undergoing with nephrectomy. PBMC were treated with H1A, nivolumab (NIV), atezolizumab (ATZ) and pembrolizumab (PEM) to evaluate their efficacy in inducing tumor cell death in an ex-vivo cytotoxicity assay. Mass cytometry was employed to determine the impact of H1A and atezolizumab on the PBMC profile. Results: MC38 tumors showed moderate response to both H1A and ATZ which was abrogated by CD8 T cell depletion. In E0771 tumors, higher percentage of complete responders was observed with H1A compared to ATZ and E0771 rechallenge revealed memory antitumor immunity with complete rejection of tumors. Patient-derived PBMC treated with H1A showed superior tumor cell killing compared to NIV, PEM and ATZ (p<0.01). While H1A treatment of PBMC induced expansion of effector NK and CD8 T cells (GZMB+ T-bet+), ATZ treatment led to enrichment of Tregs (CD25+,Foxp3+) expressing inhibitory markers PD-1 and LAG-3. Conclusions: H1A demonstrated superior antitumor activity compared to FDA-approved ICI which lays the ground for clinical testing of H1A as a next-generation immune checkpoint inhibitor for the treatment of renal cell carcinoma.
AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
Sonpavde, Guru , Kim, William Y. , Grivas, Petros , Chatta, Gurkamal , Reichert, Zachery R. , Bilen, Mehmet Asım , Srinivas, Sandy, Halabi, Susan , Burbano, Gabriela Perez , Halabi, Susan , Apolo, Andrea B , Ballman, Karla V. , Berg, Stephanie , Parikh, Rahul A , Teo, Min Yuen , Sweis, Randy F. , Geynisman, Daniel M. , Kim, Joseph W. , McGregor, Bradley A. , Morris, Michael J. , Rosenberg, Jonathan E

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: LBA531-LBA531

10.1200/jco.2024.42.4_suppl.lba531 Get It

LBA531 Background: Muscle-invasive urothelial carcinoma (MIUC) is an aggressive disease with high relapse rates. Neoadjuvant platinum-based chemotherapy (NAC) is the standard of care in patients (pts) who are cisplatin (Cis)-eligible. However, many pts are Cis-ineligible or have persistent muscle-invasive disease after NAC and surgery. We evaluated pembrolizumab (Pembro) as adjuvant therapy in pts with high-risk MIUC following surgical resection. Methods: The AMBASSADOR study is an open-label, randomized, phase III trial that enrolled pts with histologically confirmed MIUC of the bladder, upper tract, or urethra who (1) had ≥ pT2 and/or pN+ or margins+ at surgery (radical cystectomy, nephrectomy, nephroureterectomy, or ureterectomy) following NAC or (2) ≥ pT3 and/or pN+ or margins+ at surgery without NAC and were either Cis-ineligible or declined adjuvant Cis-based therapy. Pts were registered ≥4 to 16 weeks after surgery and randomized 1:1 to receive Pembro 200 mg every 3 weeks for 1 year or observation (Obs). Randomization was stratified by pathologic stage, centrally tested PD-L1 status, and prior NAC. The dual primary endpoints were disease-free survival (DFS) and overall survival (OS) with a target sample size of 739 pts and required 387 DFS and 320 OS events for final analysis. Secondary objectives included evaluation of DFS and OS in PD-L1-positive and -negative pts and assessing safety. Here we present the interim DFS and OS results. Results: Between 09/2017 and 08/2021 a total of 702 pts were randomized prior to early closure due to US FDA approval of nivolumab for MIUC pts: 354 pts to Pembro and 348 pts to Obs; 13.0% vs 21.6% withdrew from study without event in the Pembro vs Obs arms, respectively. 74 pts (21%) in the Obs arm received an immune checkpoint inhibitor. Median follow-up was 22.3 months (mos) for DFS and 36.9 mos for OS. The DFS endpoint (based on 319 events needed for interim analysis) crossed the efficacy boundary. Median DFS was 29.0 months (95% confidence interval (CI) 21.8‒not evaluable (NE)) with Pembro and 14.0 months (95% CI 9.7‒20.20) with Obs (hazard ratio (HR) 0.69 [95% CI 0.55–0.87]; p=0.0013). At the interim analysis (n = 257 events), median OS was 50.9 months (95% CI 43.9‒NE) with Pembro and 55.8 months (95% CI 53.3‒NE) with Obs (HR 0.98 [95% CI 0.76–1.26]; p=0.88). Grade 3+ adverse events occurred in 48.4% and 31.8% of pts in the Pembro and Obs arms, respectively. Conclusions: Adjuvant Pembro demonstrated a statistically significant and clinically meaningful improvement in DFS vs Obs for high-risk MIUC pts after radical surgery. The OS endpoint may have been impacted by pts on the Obs arm receiving a checkpoint inhibitor. Pembro was tolerable with no new safety signals. These results support adjuvant Pembro as a new therapeutic option for pts with MIUC with high risk for recurrence. Additional follow-up is ongoing for the final DFS/OS, PD-L1 subgroups, and ctDNA analyses. Clinical trial information: NCT03244384 .
Learning from COVID‐19 triage schemes to face the next public health emergency
DeMartino, Erin S. , Ennis, Jackson S. , Sulmasy, Daniel P., Wolf, Susan M.

Mayo Clinic

Journal of the American Geriatrics Society | January 29, 2024 | Volume: 72 | Issue: 4 | Pages: 1298-1301

10.1111/jgs.18765 | PMID 38284315 Get It

Design and evaluation of an electronic prospective medication order review system for medication orders in the inpatient setting
Ojha, Pooja, Draper, Evan , Flaker, Susan M, Siska, Mark H., Mara, Kristin C. , Kennedy, Brian , Schreier, Diana J., Anderson, Benjamin J, Draper, Evan W, Kennedy, Brian D, Mara, Kristin C , Anderson, Benjamin J

Mayo Clinic

JAMIA Open | January 28, 2024 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/jamiaopen/ooae003 | PMID 38283885 Get It

Abstract Objectives Since the 1970s, a plethora of tools have been introduced to support the medication use process. However, automation initiatives to assist pharmacists in prospectively reviewing medication orders are lacking. The review of many medications may be protocolized and implemented in an algorithmic fashion utilizing discrete data from the electronic health record (EHR). This research serves as a proof of concept to evaluate the capability and effectiveness of an electronic prospective medication order review (EPMOR) system compared to pharmacists’ review. Materials and methods A subset of the most frequently verified medication orders were identified for inclusion. A team of clinical pharmacist experts developed best-practice EPMOR criteria. The established criteria were incorporated into conditional logic built within the EHR. Verification outcomes from the pharmacist (human) and EPMOR (automation) were compared. Results Overall, 13 404 medication orders were included. Of those orders, 13 133 passed pharmacist review, 7388 of which passed EPMOR. A total of 271 medication orders failed pharmacist review due to order modification or discontinuation, 105 of which passed EPMOR. Of the 105 orders, 19 were duplicate orders correctly caught by both EPMOR and pharmacists, but the opposite duplicate order was rejected, 51 orders failed due to scheduling changes. Discussion This simulation was capable of effectively discriminating and triaging orders. Protocolization and automation of the prospective medication order review process in the EHR appear possible using clinically driven algorithms. Conclusion Further research is necessary to refine such algorithms to maximize value, improve efficiency, and minimize safety risks in preparation for the implementation of fully automated systems.